Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00138632 | Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) | PHASE1 | COMPLETED | 50 | — | — | Sep 1, 2005 | - | Nov 14, 2008 | 11 | United States, Australia |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PTK787 | DRUG | Visudyne® + PTK787, 500 mg/day |
| Placebo | DRUG | Visudyne® + Placebo |
Inclusion criteria * Male ≥ 65 years old or female ≥ 50 years old, with aged related macular degeneration * Patients with subfoveal choroidal neovascularization secondary to AMD Exclusion criteria * Eye disease that may result in visual loss during the study * Uncontrolled high blood pressure, de...